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Differential effects on gene transcription and hematopoietic
differentiation correlate with GATA2 mutant disease
phenotypes
C-E Chong1,2, P Venugopal1,2,3, PH Stokes4, YK Lee1,2, PJ Brautigan1,2, DTO Yeung1,2,5,6, M Babic1,2, GA Engler5, SW Lane7,
M Klingler-Hoffmann3, JM Matthews4, RJ D'Andrea2,5,8, AL Brown1,2, CN Hahn1,2,6 and HS Scott1,2,3,6,8,9
Heterozygous GATA2 mutations underlie an array of complex hematopoietic and lymphatic diseases. Analysis of the literature
reporting three recurrent GATA2 germline (g) mutations (gT354M, gR396Q and gR398W) revealed different phenotype tendencies.
Although all three mutants differentially predispose to myeloid malignancies, there was no difference in leukemia-free survival for
GATA2 patients. Despite intense interest, the molecular pathogenesis of GATA2 mutation is poorly understood. We functionally
characterized a GATA2 mutant allelic series representing major disease phenotypes caused by germline and somatic (s) mutations
in zinc ﬁnger 2 (ZF2). All GATA2 mutants, except for sL359V, displayed reduced DNA-binding afﬁnity and transactivation compared
with wild type (WT), which could be attributed to mutations of arginines critical for DNA binding or amino acids required for ZF2
domain structural integrity. Two GATA2 mutants (gT354M and gC373R) bound the key hematopoietic differentiation factor PU.1
more strongly than WT potentially perturbing differentiation via sequestration of PU.1. Unlike WT, all mutants failed to suppress
colony formation and some mutants skewed cell fate to granulocytes, consistent with the monocytopenia phenotype seen in
GATA2-related immunodeﬁciency disorders. These ﬁndings implicate perturbations of GATA2 function shaping the course of
development of myeloid malignancy subtypes and strengthen complete or nearly complete haploinsufﬁciency for predisposition to
lymphedema.
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INTRODUCTION
Germline predisposition to hematological malignancies is an
increasingly recognized clinical entity.1 More than 12 genes with
germline mutations leading to autosomal dominant inheritance of
hematological malignancies have been described, with several
genes, RUNX1,2 CEBPA,3 GATA2,4 ANKRD265 and DDX41,6 predip-
sosing to myelodysplastic syndrome and/or acute myeloid
leukemia (MDS/AML). With notable exceptions (for example,
DDX41), individuals with a family history of hematological
malignancies generally present at earlier ages of diagnosis
compared to sporadic disease; for example, GATA2 germline (g)
mutations transmitted as autosomal dominant predisposition to
early onset MDS/AML with often aggressive disease course and
poor outcome.4 Consistent with this, germline GATA2 mutations
were recently reported in pediatric MDS, where they were often de
novo germline events.7 Patients harboring germline GATA2
mutations can manifest an array of complex diseases with
overlapping phenotypes including Emberger syndrome (primary
lymphedema with MDS/AML),8–10 and immunodeﬁciency (ID)
disorders such as monocytopenia and mycobacterial infection
(MonoMac) syndrome,11,12 dendritic cell, monocyte, B and NK
lymphoid (DCML) deﬁciency syndrome,13,14 chronic neutropenia,15
natural killer cell deﬁciency16 and aplastic anemia,17,18 all of which
have an increased propensity to develop MDS/AML. These
mutants often possess compromised transcriptional activity and
have dominant-negative characteristics in some settings. Patients
with complete or partial gene deletions may develop Emberger
syndrome, indicating that complete GATA2 haploinsufﬁciency may
be required for predisposition to lymphedema.8,10,19
Somatic GATA2 mutations are found in speciﬁc sporadic
myeloid leukemia subtypes, that is, chronic myeloid leukemia in
blast crisis,20 monocytic AML (FAB M5)21 and cytogenetically
normal AML with mono- or biallelic CEBPA mutations.22–25 Somatic
missense mutations occur predominantly in zinc ﬁnger 1 (ZF1) of
GATA2, with the exception of sL359V20 and sR362Q22–25 in ZF2. In
contrast, no missense germline mutations occur within ZF1, rather
all occur in the ZF2 domain and the neigboring C-terminal
region.4,11,12 Phenotypic variation and unique mutational cluster-
ing separating germline and somatic GATA2 mutations imply that
they represent at least two separate entities. In this study, we
systematically analyzed genetic and clinical data of patients
carrying three most common germline GATA2 ZF2 mutations
(gT354M, gR396Q and gR398W), which revealed that although
these mutations broadly predispose to MDS/AML, they appear to
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confer unique characteristics leading to different disease subtypes
and age of onset. Using a GATA2 ZF2-mutant allelic series
representing major hematological disease subtypes, we show
differential impact on GATA2 DNA-binding afﬁnity, transactivation,
colony formation, differentiation, protein–protein interactions
and/or ZF2 structural integrity. We also report a genotype–
phenotype correlation where GATA2 mutants with residual activity
render resistance to lymphedema, while predisposing to myeloid
malignancy and/or ID, and where speciﬁc ZF2 mutations display a
propensity for particular myeloid malignancy subtypes.
MATERIALS AND METHODS
Patient information
Genetic and clinical information correlated with common germline GATA2
mutations (gT354M, gR396Q and gR398W) was available from 98
patients,4,7,8,11–16,19,26–33 gathered in studies from 27 conﬁrmed kindreds
and 7 individuals with de novomutations (Supplementary Table 1). All data
were collected with informed consent and approval from Institutional
Review Board/Human Research Ethics Committees.
Constructs
GATA2 expression constructs (human (h) pCMV6-XL6-GATA2 and mouse (m)
pCMV6-Entry-GATA2) were purchased from OriGene (Rockville, MD, USA).
A GATA2 mutant allelic series of expression constructs (human and mouse)
were generated by site-directed mutagenesis (QuickChange II, Stratagene, La
Jolla, CA, USA). FLAG-tagged hGATA2 (wild type (WT) and mutants) was sub-
cloned into the pcDNA3. A DNA fragment corresponding to the hGATA2
cDNA ZF2 domain (WT and mutants, residues 328–409) was sub-cloned into
the pET11a (Novagen, San Diego, CA, USA) and proteins were expressed in
bacteria, puriﬁed and characterized as described.34 For retroviral expression
constructs, mGata2 WT and mutant cDNA coding regions were sub-cloned
into the pMSCV-IRES-GFP (Supplementary Table 2).
Cell isolation and transplantation assays
Female C57BL/6 mice Lin− Sca1+ c-Kit+ (LSK) cells were transduced with
pMSCV-mGata2-IRES-GFP (see Supplementary Information). For transplan-
tation assays, 1 × 105 GFP+ LSK cells and 2× 105 helper bone marrow cells
were injected into the tail vein of lethally irradiated (1000 Rad) congenic
mice. All animal studies were approved by the University of Adelaide and
SA Pathology Animal Ethics Committees.
Statistical analysis
The Mann–Whitney test and Fisher’s exact test (two-tailed test) were used
to analyze statistical signiﬁcance of observed differences. Survival and time
to event analyses were performed using Kaplan–Meier, and Fine and
Gray35 methods, respectively, in R.
RESULTS
Recurrent germline GATA2 mutations are associated with different
clinical manifestation
To understand the clinical outcomes of the most common
germline GATA2 mutations, a review of in-house clinical informa-
tion and the literature was undertaken (Supplementary Table 1).
Survival and time to event (development of hematological and/or
immunological disorder) data for 94 patients with the three most
common mutations (gT354M, gR396Q and gR398W) was calcu-
lated (Table 1). Common to all mutations was the development of
MDS/AML with moderate–high penetrance (75/94, 80%). However,
age of MDS/AML onset was different among patients with
different GATA2 mutations (P = 0.04); gR396Q patients being the
earliest to develop an event (median age 16) compared with
gT354M and gR398W patients (median age 27 and 39 years,
respectively) (Figure 1a). Patients with gR398W usually presented
with an ID at around the same time as the initial diagnosis of the
myeloid disorder (median age 35 years) as did about 67% of the
gR396Q patients (Figure 1b). In contrast, gT354M patients usually
presented with MDS/AML as the ﬁrst sign of the clinical syndrome,
which may mask or confound the diagnosis of immune defects
(Figures 1b and c). Overall, the leukemia-free survival of the three
mutations was equally poor (Figure 1d). Interestingly, of 50
individuals with gT354M-driven myeloid malignancies, there were
30 AML (60%) and no chronic myelomonocytic leukemia cases,
whereas for 12 affected with gR398W there were only 2
cases associated with disease progression to AML (17%), but
4 chronic myelomonocytic leukemia (33%) (Table 2). No chronic
myelomonocytic leukemia was seen in the 18 gR396Q
cases, although lymphedema was reported in 1 individual.30
Collectively, this data demonstrate prognostically important
mutation-speciﬁc differences in disease subtype, penetrance and
outcome.
GATA2 mutants display differentially altered DNA binding via
different mechanisms
To investigate the functional basis of differences in GATA2-driven
disease, we generated a mutant allelic series for human GATA2
(hGATA) representing major disease phenotypes: MDS/AML
(gT354M and gT355del),4 chronic myeloid leukemia in blast crisis
(sL359V),20 Emberger syndrome (gR361L and gC373R),10 acute
monocytic leukemia (AML-M5),21 biallelic CEBPA AML
(sR362Q)22,23,36,37 and MonoMAC/DCML deﬁciency syndrome (ID
with MDS/AML, gR398W)11–14 (Figure 2a). Previously reported
mutants gT354M, gT355del and sL359V were included for the
purposes of comparison.4 We also made corresponding mutant
murine GATA2 clones (mGATA2). In HEK293 cells, all mutant
proteins displayed nuclear localization similar to WT GATA2
(Supplementary Figure S1), indicating that, unlike RUNX1, disrup-
tion of the nuclear localization signal is not a major mechanism for
GATA2 functional dysregulation.4 Examination of DNA binding to
Table 1. Disease spectrum of individuals carrying recurrent GATA2 mutations







ES (lymphedema+MDS) No symptoms Total
gT354M (n = 64) 39 (64%) 8 (13%) 4 (7%) 0 10 (16%) 61a
gR396Q (n= 19) 6 (33%) 10 (55%) 1 (6%) 1 (6%) 0 18a
gR398W (n= 15) 2 (13%) 10 (67%) 2 (13%) 0 1 (7%) 15
Sub-total 47 28 7 1 11 94
Abbreviations: AML, acute myeloid leukemia; aCML, atypical chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; ES, Emberger syndrome; ID,
immunodeﬁciency; MDS, myelodysplastic syndrome. aFour GATA2 patients (three gT354M and one gR396Q) for whom age of death/age at diagnosis was
unknown were excluded from analysis in Figure 1 (see Supplementary Table 1). Predominant phenotype (bold).
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known GATA2-responsive elements using western blotting
electromobility shift assays revealed a single GATA2–DNA com-
plex for WT GATA2 (Figures 2b and c). mGATA2 mutant proteins
and hGATA2 (Supplementary Figures S2 and S3) exhibited very
similar DNA-binding patterns for both hGM-CSF and hTCRD
probes. A range of relative DNA-binding capabilities were
identiﬁed that could be divided into three classes. sL359V
displayed no signiﬁcant reduction in binding (Class I) in contrast
to gT354M, sR362Q, gR398W and sL321F (ZF1 mutant), which had
reduced but detectable binding (Class II), whereas gT355del,
gR361L, gC373R and gR396Q (Class III) displayed little or no
detectable binding (Figure 2c and Supplementary Figures S2).
DNA binding was conﬁrmed and quantiﬁed using isothermal
titration calorimetry (Figure 2d, Supplementary Table 3 and
Supplementary Figure S5). sL359V showed binding efﬁciency
similar to WT, Class II mutants had 1.7- to 5.7-fold reduction,
gT355del had 11-fold reduction in afﬁnity, whereas gR361L and
gC373R (Emberger syndrome mutants) were below the limits of
detection. We also included gR396Q in this assay as in one report,
a Japanese girl with gR396Q, in addition to MDS and ID,
developed lymphedema.30 This mutant showed 13-fold reduction
in afﬁnity. To date, neither Class I nor II mutants have been
associated with lymphedema and we predict individuals carrying
Class III mutants (gT355del, gR361L, gC373R and gR396Q) to be
predisposed to lymphedema.
Our previous work indicated that gC373R is poorly folded due
to mutation of a zinc-coordinating residue and gT354M is partially
unfolded34 (Figure 2a). Homology modeling indicated that
mutation of positively charged arginine residues (gR361L,
sR362Q, gR396Q and gR398W) probably disrupts critical interac-
tions with DNA without affecting ZF2 structure (Supplementary
Figure S6). To test the effect of mutation on ZF2, far-UV circular
dichroism spectropolarimetry and one-dimensional proton
nuclear magnetic resonance spectroscopy were used to assess
secondary and tertiary structure, respectively. gT355del was
shown to be partially unfolded, similar to gT354M, with high
levels of secondary structure, but moderate disruptions of tertiary
structure compared with WT. The arginine mutants have WT
secondary and tertiary structure (Supplementary Figure S7). There
was no correlation between the mechanism of disruption and the
magnitude of DNA-binding reduction, suggesting that functional
Table 2. Recurrent germline GATA2 ZF2 mutations and their
association with myeloid malignancy subtypes
Mutation Myeloid malignancy subtypes
aCML/CMML MDS AML Totala P-valueb
gT354M 1 (2%)c 19 (38%) 30 (60%) 50
gR396Q 0 14 (78%) 4 (22%) 18 o0.001
gR398W 4 (33%)d 6 (50%) 2 (17%) 12
80
Abbreviations: AML, acute myeloid leukemia; aCML, atypical chronic
myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS,
myelodysplastic syndrome. aUnaffected individuals (n= 11) or individuals
with ID syndrome alone (n= 7) were excluded from statistical analysis.
b3 ×3 Fisher’s exact probability test (two-tailed test) for GATA2 mutants,
aCML/CMML, MDS and AML. caCML. dCMML (unique for gR398W).
Predominant phenotype (bold).
Figure 1. Time to event analyses were performed using the cumulative incidence function with adjustment for competing risk. (a) Cumulative
incidence of MDS/AML stratiﬁed by GATA2 mutations. (b) Cumulative incidence of ID for three germline GATA2 mutations. (c) Cumulative
incidence of ID syndrome in gT354M patients. AML, MDS and death from any cause were considered competing risk events that prevent or
mask the development of ID. (d) Kaplan–Meier plot of leukemia transformation free survival for GATA2 mutants. An event is either diagnosis of
AML or death. All P-values (log-rank test) are for overall global comparisons.
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assays are required to determine DNA-binding afﬁnity. Collec-
tively, alterations to the integrity of ZF2 structure and mutation of
key DNA-binding residues can independently and variably disrupt
GATA2 DNA binding.
GATA2 mutants display differentially altered transactivation
activity and protein–protein interactions
To determine the effect of GATA2 mutations on the ability to
transactivate transcription, we performed luciferase reporter
assays on known GATA2-responsive promoters (LYL1 and CSF1R)
and enhancer (CD34). All mutants displayed a reduced ability to
transactivate transcription from at least one of these GATA2-
responsive elements relative to WT GATA2, except for sL359V
(Figure 3 and Supplementary Figures S8a and b), which we and
others have shown displays WT or mild gain-of-function (GOF)
activity.4,20 Class III mutants with least DNA-binding afﬁnity
(gT355del, gR361L and gC373R; Figure 3) showed the most
marked reduction in transactivation, including complete abroga-
tion of transactivation in some instances, whereas Class II mutants
(gT354M, sR362Q, gR398W and sL321F (Supplementary
Figure S8c)) displayed residual transactivation capacity.
Previously, we have shown that GATA2 and PU.1 (SPI1)
synergistically upregulate CSF1R promoter activity.4 Here, all
GATA2 mutants (except for sL359V) showed reduced synergistic
transactivation with PU.1 (Figure 3c); however, all mutants
retained some ability to activate transcription with PU.1 relative
to PU.1 alone (Supplementary Figure S8d). Even mutants with
complete loss of DNA binding were able to co-activate with PU.1.
Consistent with this, in co-immunoprecipitation assays, all GATA2
mutants maintained an ability to interact with PU.1 (Figure 4 and
Supplementary Figure S9), which has been shown to occur via
ZF2.38 Strikingly, gT354M and gC373R showed enhanced afﬁnity
for PU.1. Together these data show that although transactivation
via GATA2-responsive elements generally correlates with DNA-
binding activity, interaction with and co-activation with PU.1
differs between mutants in a non-DNA-binding-dependent
manner.
GATA2 mutants perturb differentiation of hematopoietic stem and
progenitor cells
We next investigated the effects of GATA2 mutations on
hematopoiesis using colony-forming assays. mGATA2 WT and
mutants were retrovirally transduced into murine LSK cells using
pMSCV-mGata2-IRES-GFP and sorted for green ﬂuorescent protein
(GFP) positivity. Similar levels of mGATA2 WT and mutants in LSK
cells were achieved and conﬁrmed using quantitative reverse
transcriptase-PCR (Supplementary Figure S10). As shown
previously,39 WT GATA2 was able to efﬁciently suppress colony
formation and multilineage differentiation of progenitor cells, with
the exception of the erythroid lineage (colony forming unit-
erythroid, BFU-E) (Figure 5). All GATA2 mutants displayed
signiﬁcant de-repression of colony formation, restoring colony
numbers to similar to empty vector (EV) (Figure 5a). Interestingly,
this included sL359V, indicating that de-repression of colony-
forming ability is, at least in some cases, uncoupled from effects
on DNA binding and transactivation ability. Granulocyte colony-
forming units mirrored total colony numbers (Figure 5b). A similar
increasing trend was also observed in colony formation for
granulocyte–macrophage/granulocyte, erythrocyte, monocyte
and megakaryocyte progenitors (Figure 5c). In contrast to
Figure 2. Mutations in ZF2 domain perturb GATA2 activity and function. (a) Location of missense mutations in GATA2 ZF2 domain investigated
in this study and their associated phenotypes. (b) GATA2 mutants differ in their DNA-binding afﬁnity. Expression of full-length mGATA2
proteins (nuclear extracts (NE); 10 μg each) detected by western blotting with an anti-GATA2 antibody. (c) GATA2 NEs (10 μg) were bound to
hGM-CSF and hTCRD enhancer oligonucleotide probes and western blotting electromobility shift assays were performed using anti-GATA2
antibody. Oligonucleotide probes with mutated GATA-binding site (Mut) for hGM-CSF or hTCRD enhancer were used as negative controls. ND,
not determined. (d) DNA-binding afﬁnity of hGATA2 ZF2 domain quantiﬁed by isothermal titration calorimetry.
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granulocyte CFU formation, not all GATA2 mutants de-repressed
macrophage CFUs, with Class I and II mutants with the most
preserved DNA-binding activity (sL359V, gT354M and sR362Q)
maintaining WT levels of macrophage CFU repression (Figure 5d).
Notably, the two somatic mutations also promoted erythroid
differentiation (Figure 5e). This suggests that there are both
DNA-dependent and independent effects of GATA2 mutations on
myeloid lineage differentiation, with mutations associated most
frequently with development of acute leukemic states (gT354M
with familial AML, sL359V with chronic myeloid leukemia in blast
crisis and sR362Q with sporadic AML) maintaining an ability to
repress macrophage progenitor differentiation.
Figure 3. GATA2 mutants display variable loss of transactivation capacity on known GATA2-responsive elements. (a) HEK293 cells were co-
transfected with GATA2-responsive CD34 enhancer-LUC reporter and GATA2 (WT or mutants) expression constructs or EV. (b) Cos-7 cells were
co-transfected with LYL1 promoter-LUC reporter and GATA2 expression constructs. (c) GATA2 expression constructs were co-transfected
with CSF1R promoter-LUC into Cos-7 cells (white columns). Inset, a magniﬁed view of the ﬁrst nine conditions. The synergistic effect of GATA2
with PU.1 on the CSF1R promoter was investigated by co-transfecting GATA2 expression constructs with PU.1 (grey columns). Results are
fold change compared with EV (± s.e.m., four independent biological replicates). Differences between WT (hatch) and mutants were
calculated. ns: not signiﬁcant, *Po0.05 and **Po0.01.
Figure 4. GATA2 mutants alter interaction with PU.1. (a) PU.1 was co-immunoprecipitated (co-IP) with GATA2 using anti-FLAG antibody
(forward). (b) GATA2 was co-IP with PU.1 using anti-PU.1 antibody (reverse). Western blot analyses were performed with anti-GATA2 or anti-
PU.1 antibody. gT354M and gC373R (*) show increased binding activity to PU.1.
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To examine in vivo effects of GATA2 mutants on hematopoiesis,
we transplanted transduced LSK cells (EV, GATA2 WT, gT354M or
gC373R), along with untransduced helper marrow, into lethally
irradiated recipient mice and monitored the percentage of GFP-
positive cells in peripheral blood as a measure of contribution to
engraftment (Supplementary Table 4 and Supplementary
Figure S11). GFP-positive cells were observed in the peripheral
blood of all mice transduced with EV at time points up to
20 weeks post transplantation (n= 8/8). Consistent with the ability
of increased GATA2 expression to block hematopoiesis in normal
mice and to impair progenitor growth (above), only 40% of mice
transplanted with WT GATA2 LSK had GFP-positive cells (4/10) and
no GFP-positive cells were seen at time points of 10 weeks or later.
Similar numbers of mice with GFP contribution to engraftment
were observed for both GATA2 mutants (T354M n= 4/9, C373R
n= 5/7), although in each case at least 2 mice maintained GFP-
positive cells at 14 weeks, indicating potential loss of inhibitory
activity of WT GATA2 in this context. Mice were aged for up to
12 months and during this time no differences in survival or
development of hematological disorders were observed.
DISCUSSION
Germline GATA2 mutations underlie the development of hema-
tological, immunological and lymphatic disorders. Diverse pheno-
types in patients harboring different germline GATA2 mutations
have led us to investigate the effect of the three most prevalent
GATA2 missense mutations (gT354M, gR396Q and gR398W). These
mutants appear to impact on disease subtypes (for example, MDS/
AML and chronic myelomonocytic leukemia) and exhibit differ-
ences in age of onset. Recently, Ding et al.40 reported two cases of
gR396Q mutation in patients who developed MDS at younger age,
consistent with our data that it predisposes predominantly to MDS
and with early onset. These data support the concept of genetic
‘predestination’ where initiator or founder mutations in a protein
or even domain confer increased tendency to direct or constrain
the impact of subsequent mutations and phenotypes.41,42
Recurrent and clinically important GATA2 mutations in ZF2
perturb protein folding and/or DNA-binding afﬁnity. Homology
modeling predicts that the four arginine residues (R361, R362,
R396 and R398) and L3594 directly contact DNA, whereas T354,
T355 and C373 are more likely involved in maintaining ZF2
structural integrity. We have proposed three classes of GATA2
mutations based on DNA-binding afﬁnity (Figure 6); enhanced,
reduced and greatly reduced. Interestingly, mutations within each
class lead to different clinical outcomes. The Class I mutant is a
unique case of somatic mutation associated with driving chronic
myeloid leukemia into blast crisis20 and has not been seen in
MDS/AML. Class II mutants are associated with myeloid malig-
nancies and/or ID. In addition to Class II phenotypes, Class III
mutants also predispose to primary lymphedema (we predict this
for gT355del) consistent with complete loss-of-function (LOF) of
one GATA2 allele being required for predisposition to primary
lymphedema, as proposed by us and others.8,10,19 This is further
supported by our ﬁndings where heterozygous conditional
knockout of Gata2 results in defective lymphatic vessel structure
and vascular transport in adult mice.34 Together, these data
support what is seen clinically, where germline GATA2 mutants
with a threshold of residual activity predispose to myeloid
malignancy and/or ID, but not to lymphedema.
Our results together with the published data suggest that DNA-
binding afﬁnity alone cannot explain the association between
speciﬁc GATA2 ZF2 mutations and hematological malignancy
subtypes. We show for the ﬁrst time that ZF2 mutations can
drastically affect its ability to interact with PU.1, a known key
myeloid transcription factor-binding partner. Speciﬁcally, gT354M
and gC373R with altered ZF2 tertiary structure bind PU.1 more
tightly. PU.1 is an E-twenty-six (ETS) transcription factor that
Figure 5. GATA2 mutants differentially impact clonogenic expansion and hematopoietic differentiation. (a) Enumeration of absolute colony
numbers. GATA2 WT (hatch) was used as a comparator for all analyses. (b–e) Colonies were typed by morphology and numbers were reported.
(b) Granulocyte CFU (CFU-G), (c) colony formation for granulocyte–macrophage/granulocyte, erythrocyte, monocyte and megakaryocyte
progenitors (CFU-GM/GEMM), (d) macrophage CFU (CFU-M) and (e) BFU-E. All results are plotted as mean± s.e.m. with n independent
biological replicates. ns: not signiﬁcant, *Po0.05 and **Po0.01.
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induces expression of genes pivotal to myeloid differentiation.43
Although mutations in PU.1 gene and its regulatory region are
relatively rare in cytogenetically normal MDS and AML,44,45 studies
have shown that PU.1 activity is compromised in many AML cases.
For instance, fusion protein pro-myelocytic leukemia ZF/retinoic
acid receptor alpha (RARA) directly interacts with PU.1 resulting in
sequestration of PU.1.46 Similarly, enhanced binding by these
GATA2 mutants may sequester both GATA2 and PU.1 from their
normal roles in myelopoiesis. How ZF2 mutations affect the
binding to other GATA2-binding partners such as CEBPA remains
to be determined. We hypothesize that some GATA2 mutants may
impair hematopoiesis via aberrant sequestration of key hemato-
poietic transcription factors resulting in disruption of normal
cellular processes including differentiation, proliferation and
survival. Further, gT354M and gR396Q were reported to attenuate
chromatin occupancy, reduce endogenous target gene activation
and disrupt endogenous GATA2 WT binding suggestive of
dominant-negative properties.47,48 Moreover, our colony-
formation assays are consistent with those reported previously for
gR396Q.47 Hence, the extent of loss of DNA binding and
transactivation, and changes to protein–protein interactions may
contribute to the clinically diverse outcomes of GATA2-related
disease.
GATA2 WT or mutants have varying effects on growth and
differentiation of hematopoietic progenitors. Expression of GATA2
WT results in a profound block in clonogenic growth, colony
numbers and differentiation in vitro. This is consistent with
elevated GATA2 levels in hematopoietic stem cells driving
quiescence49,50 and the role of GATA2 in maintaining the
‘stemness’ of these cells.51,52 Expression of GATA2 is known to
perturb normal hematopoiesis and cause pancytopenia in
transplanted mice.39 Here, all GATA2 mutants, independent of
DNA-binding afﬁnity, displayed loss of progenitor growth inhibi-
tion and we speculate that under certain conditions GATA2
mutants are unable to restrain growth/cycling, contributing to
stem cell pool depletion and exhaustion. This may be particularly
important on a background of persistent infection and/or
hematopoietic stress such as in bone marrow failure, as it has
been proposed previously for MonoMAC/DCML deﬁciency
syndromes.11–14 Colony-formation assays show an increase in
granulocytic progenitors following expression of GATA2 mutants
consistent with skewed differentiation causing the monocytope-
nia observed in ID syndrome. Although it is not clear why
monocytes are preferentially depleted, GATA2 mutated patients
have better preservation of neutrophils (granulocytes) compared
with GATA2 WT MDS or idiopathic aplastic anemia patients.17,19
Conversely, erythroid progenitors are selectively resistant to the
suppressive effects of sL359V and sR362Q allowing for colony
expansion. Recently, Ping et al.53 discovered a subset of acute
erythroid leukemia patients with somatic GATA2 mutations in ZF1
domain. Although there is no clinical evidence directly linking
sL359V and sR362Qs to erythroid leukemia, these GATA2 ZF2
mutants resemble GATA2 ZF1 mutations, in that they commonly
arise in a background of pre-existing mutations (for example,
CEBPA and BCR-ABL). In contrast to the predominance of GATA2
germline mutations in ZF2, most somatic GATA2 mutations cluster
within ZF1. GATA2 ZF1 (for example, sL321F) mutations and a sole
ZF2 (sR362Q) mutation are often associated with AML harboring
Figure 6. Summary of functional assays for GATA2 mutant allelic series in this study. GATA2 mutants are listed in descending order of DNA-
binding afﬁnity. Results of transactivation, co-IP, subcellular localization, structural changes and colony assays are summarized. DEL indicates
partial or whole gene deletion and mutants with premature termination; Nc, nuclear; ND, not determined. #See Greif et al.24 *See Kazenwadel
et al.34 ^See Cortes-Lavaud et al.47
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biallelic CEBPA mutations (biCEBPA AML; ~ 25% contain ZF1 or
sR362Q mutations).22–24,36,37 This association appears to be less for
germline ZF2 mutations, which seem rarely to co-occur with
CEBPA mutations implying different leukemogenic mechanisms
for ZF1 and ZF2 mutations. Acquired initiator mutations in CEBPA
may generate permissive pre-leukemic environments enabling
selective forces for ZF1 or particular ZF2 (R362) mutations. Various
substitutions of R362 (sR362Q/P/G) have been reported in
cytogenetically normal pediatric AML36,37 and adult biCEBPA
AML,22,23 highlighting the importance of changes to this DNA-
binding residue in sporadic leukemia development.
Our functional studies on clinically important GATA2 ZF2
mutants provide new insights into mechanisms interacting with
environmental stresses on the hematopoietic and lymphatic
compartments that contribute to myeloid malignancies, ID with
a unique spectrum of permissive infections and/or lymphedema.
We demonstrate the complexity of amino acid mutation speciﬁc
phenotypes important in sporadic AML subtypes in addition to
hereditary MDS/AML subtypes. Further mechanistic studies are
warranted to better understand the complex interplay of genetic
and environment causal factors in attempt to treat or prevent
development of these disorders.
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